GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actelion Ltd (XSWX:ATLNE) » Definitions » Price-to-Owner-Earnings

Actelion (XSWX:ATLNE) Price-to-Owner-Earnings : 36.06 (As of May. 17, 2024)


View and export this data going back to . Start your Free Trial

What is Actelion Price-to-Owner-Earnings?

As of today (2024-05-17), Actelion's share price is CHF65.26. Actelion's Owner Earnings per Share (TTM) ended in Mar. 2017 was CHF1.81. It's Price-to-Owner-Earnings for today is 36.06.


The historical rank and industry rank for Actelion's Price-to-Owner-Earnings or its related term are showing as below:

XSWX:ATLNE' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.72   Med: 25.44   Max: 2686.36
Current: 36.07

During the past 13 years, the highest Price-to-Owner-Earnings of Actelion was 2686.36. The lowest was 12.72. And the median was 25.44.


XSWX:ATLNE's Price-to-Owner-Earnings is not ranked
in the Biotechnology industry.
Industry Median: 34.045 vs XSWX:ATLNE: 36.07

As of today (2024-05-17), Actelion's share price is CHF65.26. Actelion's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2017 was CHF0.00. Therefore, Actelion's PE Ratio for today is N/A.

As of today (2024-05-17), Actelion's share price is CHF65.26. Actelion's EPS without NRI for the trailing twelve months (TTM) ended in was CHF0.00. Therefore, Actelion's PE Ratio without NRI for today is N/A.

During the past 13 years, Actelion's highest PE Ratio without NRI was 42.66. The lowest was 11.02. And the median was 20.83.


Actelion Price-to-Owner-Earnings Historical Data

The historical data trend for Actelion's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actelion Price-to-Owner-Earnings Chart

Actelion Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Actelion Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Actelion's Price-to-Owner-Earnings

For the Biotechnology subindustry, Actelion's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actelion's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actelion's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Actelion's Price-to-Owner-Earnings falls into.



Actelion Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Actelion's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=65.26/1.81
=36.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Actelion  (XSWX:ATLNE) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Actelion Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Actelion's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Actelion (XSWX:ATLNE) Business Description

Traded in Other Exchanges
N/A
Address
Actelion is a Swiss biopharmaceutical firm with several products on the market, largely focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri treat various stages of the disease via different methods of administration. Zavesca is a second-line option for Gaucher disease, and Valchlor treats a rare form of blood cancer. Actelion has created a global commercial infrastructure for its approved orphan drugs and has supplemented its internal pipeline through in-licensing and acquisitions.

Actelion (XSWX:ATLNE) Headlines

No Headlines